<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Clinical complications of atherosclerosis like myocardial infarction, stroke and peripheral arterial disease still represent the leading cause of mortality and morbidity in the world [
 <xref rid="B9-marinedrugs-17-00374" ref-type="bibr" class="xref">9</xref>,
 <xref rid="B19-marinedrugs-17-00374" ref-type="bibr" class="xref">19</xref>]. Among patients who are receiving appropriate treatment with statins, the rates of CV events remain high [
 <xref rid="B20-marinedrugs-17-00374" ref-type="bibr" class="xref">20</xref>,
 <xref rid="B21-marinedrugs-17-00374" ref-type="bibr" class="xref">21</xref>]. In addition, recent genetic [
 <xref rid="B22-marinedrugs-17-00374" ref-type="bibr" class="xref">22</xref>,
 <xref rid="B23-marinedrugs-17-00374" ref-type="bibr" class="xref">23</xref>,
 <xref rid="B24-marinedrugs-17-00374" ref-type="bibr" class="xref">24</xref>] and Mendelian randomization studies [
 <xref rid="B25-marinedrugs-17-00374" ref-type="bibr" class="xref">25</xref>,
 <xref rid="B26-marinedrugs-17-00374" ref-type="bibr" class="xref">26</xref>] have highlighted triglyceride levels as an independent risk factor for the incidence of ischemic events. Therefore, there is renewed interest in targeting triglycerides aiming at reducing the residual cardiovascular risk [
 <xref rid="B21-marinedrugs-17-00374" ref-type="bibr" class="xref">21</xref>]. Lifestyle modification remains the starting point of therapy for the hypertriglyceridemia, followed by fibrates and n-3 PUFAs administration [
 <xref rid="B27-marinedrugs-17-00374" ref-type="bibr" class="xref">27</xref>].
</p>
